Blueprint Medicines (BPMC) Stock Statistics & Valuation Metrics

Blueprint Medicines has a market cap or net worth of ―. The enterprise value is ―.

Blueprint Medicines has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Blueprint Medicines’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Blueprint Medicines is ―. Blueprint Medicines’s PEG ratio is ―.

In the last 12 months, Blueprint Medicines had revenue of ― and earned ― in profits. Earnings per share was ―.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

Blueprint Medicines pays an annual dividend of ―, resulting in a dividend yield of ―

Blueprint Medicines upcoming earnings date is ―, ―.

Blueprint Medicines as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Blueprint Medicines has paid ― in taxes.

Blueprint Medicines EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Blueprint Medicines has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Blueprint Medicines is ―, which is 11.43% higher than the current price. The consensus rating is ―